European Journal of Nuclear Medicine and Molecular Imaging · 2014 · 397 citations · 35 references
MedicineNuclear MedicineOncologyEndocrine OncologyRadionuclide TherapyTherapeutic Nuclear MedicineEndocrine Toxicity ManagementNeuroendocrine Tumor TherapyPeptide Receptor Radionuclide TherapyRadiation TherapyRadiopharmaceutical TherapyTargeted Radionuclide TherapyBeta-emitting Radioligand TherapyBeta-emitting RadionuclidesLiver Metastases TreatmentLiver Tumor TherapyNeuroendocrine Liver MetastasisRadiotracers Targeting Somatostatin ReceptorsTumor Targeting Specificity
PURPOSE: Radiopeptide therapy using a somatostatin analogue labelled with a beta emitter such as (90)Y/(177)Lu-DOTATOC is a new therapeutic option in neuroendocrine cancer. Alternative treatments for patients with refractory disease are rare. Here we report the first-in-human experience with (213)Bi-DOTATOC targeted alpha therapy (TAT) in patients pretreated with beta emitters. METHODS: Seven patients with progressive advanced neuroendocrine liver metastases refractory to treatment with (90)Y/(177)Lu-DOTATOC were treated with an intraarterial infusion of (213)Bi-DOTATOC, and one patient with bone marrow carcinosis was treated with a systemic infusion of (213)Bi-DOTATOC. Haematological, kidney and endocrine toxicities were assessed according to CTCAE criteria. Radiological response was assessed with contrast-enhanced MRI and (68)Ga-DOTATOC-PET/CT. More than 2 years of follow-up were available in seven patients. RESULTS: The biodistribution of (213)Bi-DOTATOC was evaluable with 440 keV gamma emission scans, and demonstrated specific tumour binding. Enduring responses were observed in all treated patients. Chronic kidney toxicity was moderate. Acute haematotoxicity was even less pronounced than with the preceding beta therapies. CONCLUSION: TAT can induce remission of tumours refractory to beta radiation with favourable acute and mid-term toxicity at therapeutic effective doses.
35
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Chris Parker, Sten Nilsson, Daniel Heinrich et al. · New England Journal of Medicine · 2013 · 3.3K citations
Dik J. Kwekkeboom, Wouter W. de Herder, Boen L.R. Kam et al. · Journal of Clinical Oncology · 2008 · 1.4K citations · Full text
Medicine, Nuclear Medicine, Oncology +17
Targeted α particle immunotherapy for myeloid leukemia
Joseph G. Jurcic, Steven M. Larson, George Sgouros et al. · Blood · 2002 · 467 citations · Full text
Medicine, Hematology, Oncology +14